Immunoparesis status in immunoglobulin light chain amyloidosis at diagnosis affects response and survival by regimen type

Clinical tools to guide in the appropriate treatment selection in immunoglobulin light chain (AL) amyloidosis are not well developed. We evaluated the response and outcome for various regimens at first-line treatment (n=681) and first progression (n=240) stratified by the immunoparesis status at dia...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Haematologica
Auteurs principaux: Muchtar, Eli, Dispenzieri, Angela, Kumar, Shaji K., Dingli, David, Lacy, Martha Q., Buadi, Francis K., Hayman, Suzanne R., Kapoor, Prashant, Leung, Nelson, Chakraborty, Rajshekhar, Russell, Stephen, Lust, John A., Lin, Yi, Go, Ronald S., Zeldenrust, Steven, Kyle, Robert A., Rajkumar, S. Vincent, Gertz, Morie A.
Format: Artigo
Langue:Inglês
Publié: Ferrata Storti Foundation 2016
Sujets:
Articles
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5060027/
https://ncbi.nlm.nih.gov/pubmed/27479823
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2016.147041
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires